Frontiers in pathophysiology and management of thrombotic thrombocytopenic purpura
Abstract Thrombotic thrombocytopenic purpura (TTP) is a fatal disease in which platelet-rich microthrombi cause end-organ ischemia and damage. TTP is caused by markedly reduced ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) activity. Hereditary or congenital TTP (cTTP) is caused by ADAMTS13 gene mutations. In acquired or immune TTP (iTTP), ADAMTS13 activity is reduced by anti-ADAMTS13 autoantibodies. TTP is characterized by thrombocytopenia, hemolytic anemia, fever, renal dysfunction, and neuropsychiatric symptoms. Therapeutic plasma exchange (TPE) and immunosuppressive therapy are the mainstays of treatment. As untreated TTP has a high mortality rate, immediate initiation of TPE is recommended when TTP is suspected. Conventionally, corticosteroids have been used for immunosuppressive therapy. Current drug therapies include rituximab, an anti-CD20 antibody that is effective in newly diagnosed cases and refractory cases, as well as for relapse prevention, and caplacizumab, an anti- von Willebrand factor (VWF) nanobody that inhibits the binding of platelets to VWF and prevents microthrombi formation. Recombinant human ADAMTS13 is a promising treatment for cTTP. Although these therapeutic advances have improved the outcomes of TTP, early diagnosis and prompt initiation of appropriate therapy are necessary to achieve these outcomes..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:117 |
|---|---|
| Enthalten in: |
International journal of hematology - 117(2023), 3 vom: 09. Feb., Seite 331-340 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kubo, Masayuki [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
ADAMTS13 protein |
|---|
| Anmerkungen: |
© Japanese Society of Hematology 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s12185-023-03552-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2134199148 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2134199148 | ||
| 003 | DE-627 | ||
| 005 | 20230506161947.0 | ||
| 007 | tu | ||
| 008 | 230506s2023 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12185-023-03552-8 |2 doi | |
| 035 | |a (DE-627)OLC2134199148 | ||
| 035 | |a (DE-He213)s12185-023-03552-8-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Kubo, Masayuki |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Frontiers in pathophysiology and management of thrombotic thrombocytopenic purpura |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © Japanese Society of Hematology 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Abstract Thrombotic thrombocytopenic purpura (TTP) is a fatal disease in which platelet-rich microthrombi cause end-organ ischemia and damage. TTP is caused by markedly reduced ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) activity. Hereditary or congenital TTP (cTTP) is caused by ADAMTS13 gene mutations. In acquired or immune TTP (iTTP), ADAMTS13 activity is reduced by anti-ADAMTS13 autoantibodies. TTP is characterized by thrombocytopenia, hemolytic anemia, fever, renal dysfunction, and neuropsychiatric symptoms. Therapeutic plasma exchange (TPE) and immunosuppressive therapy are the mainstays of treatment. As untreated TTP has a high mortality rate, immediate initiation of TPE is recommended when TTP is suspected. Conventionally, corticosteroids have been used for immunosuppressive therapy. Current drug therapies include rituximab, an anti-CD20 antibody that is effective in newly diagnosed cases and refractory cases, as well as for relapse prevention, and caplacizumab, an anti- von Willebrand factor (VWF) nanobody that inhibits the binding of platelets to VWF and prevents microthrombi formation. Recombinant human ADAMTS13 is a promising treatment for cTTP. Although these therapeutic advances have improved the outcomes of TTP, early diagnosis and prompt initiation of appropriate therapy are necessary to achieve these outcomes. | ||
| 650 | 4 | |a Thrombotic thrombocytopenic purpura | |
| 650 | 4 | |a ADAMTS13 protein | |
| 650 | 4 | |a Plasma exchange | |
| 650 | 4 | |a Rituximab | |
| 650 | 4 | |a Caplacizumab | |
| 700 | 1 | |a Matsumoto, Masanori |0 (orcid)0000-0002-7243-3126 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of hematology |d Springer Nature Singapore, 1991 |g 117(2023), 3 vom: 09. Feb., Seite 331-340 |w (DE-627)170577996 |w (DE-600)1076875-0 |w (DE-576)105258091 |x 0925-5710 |7 nnns |
| 773 | 1 | 8 | |g volume:117 |g year:2023 |g number:3 |g day:09 |g month:02 |g pages:331-340 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s12185-023-03552-8 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 951 | |a AR | ||
| 952 | |d 117 |j 2023 |e 3 |b 09 |c 02 |h 331-340 | ||